Higher anti-depressant dose and major adverse outcomes in moderate chronic kidney disease: a retrospective population-based study

Table 3 Association between anti-depressant dose and 30-day outcomes

	Number of events, n (%)		Relative risk (Unadjusted)	Relative risk (Adjusted)	Absolute risk reduction (%)
	Higher dose^£	Lower dose^¶	(95% CI)	(95% CI)^¥	Absolute risk reduction (%)
	Higher dose^£	Lower dose^¶			(95% CI)
	N = 36,651	N = 81,160			(95% CI)
Hospital admission with head CT scan	400 (1.09)	1,033 (1.27)	0.86 (0.76 – 0.96)	0.90 (0.80 – 1.02)	(…)
All-cause mortality	278 (0.76)	791 (0.97)	0.78 (0.68 – 0.89)	0.82 (0.71 – 0.95)	0.22 (0.10 – 0.33)

^£Higher dose of anti-depressant defined as > 20 mg/day of paroxetine, > 20 mg/day of mirtazapine, or > 37.5 mg/day of venlafaxine.
^¶Lower dose of anti-depressant defined as ≤ 20 mg/ day of paroxetine, ≤ 20 mg/day of mirtazapine, or ≤ 37.5 mg/day of venlafaxine.
^¥Adjusted for 15 covariates (see Methods).
(…) Absolute risk difference was not calculated as adjusted relative risk was not statistically significant for this outcome.
Patients prescribed the lower anti-depressant dose served as the referent group.
Abbreviations: CI confidence interval, CT computed tomography.

ISSN: 1471-2369